News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Millenia Hope And Suninvest Sign MMH Malarex Agreement



1/22/2007 1:06:07 PM

WILMINGTON, DE, and MONTREAL, QC, Jan. 22 /PRNewswire-FirstCall/ - Millenia Hope Inc., , announced today that, through the efforts of its Canadian Law Firm, Heenan Blaikie, with the support of one of its senior partners, the Rt. Honorable Jean Chretien, former Prime Minister of Canada, it has signed an MOU (Memorandum of Understanding) with Suninvest of Angola, Africa to establish a production facility in Angola. This plant would supply an envisioned 500,000- treatment Malarex/MMH 18 order from the Angolan government, once Malarex/MMH 18 has been homologated, as well as supplying the demand from the rest of the African region. Millenia Hope, a Montreal, Canada based U.S. Biopharma, has dedicated its resources for the past nine years to developing its anti-malarial drug, Malarex/MMH 18.

Leonard Stella, Chairman, and CEO of Millenia Hope, stated, "We are very pleased to have concluded this crucial MOU with Suninvest. Once the infrastructure is in place, we will have a true African presence in our ongoing battle against the devastation of malaria in the African continent."

ABOUT MILLENIA HOPE:

Millenia Hope develops innovative treatments and products that enhance the quality of life, has put in place programs to fight major infectious diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.

SAFE HARBOR STATEMENTS:

Certain statements made in the release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Millenia Hope/Millenia Hope Biopharma that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services, and markets.

MILLENIA HOPE BIOPHARMA

CONTACT: Mr. Leonard Stella, CEO, (514) 846-5757, (514) 288-8822,leostella@milleniahope.com, http://www.milleniahope.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES